Policosanol Cholesterol Meta-analysis: What the Evidence Says

Quick Answer

Policosanol Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Oxidative stress has been reported in kidney disease, cardiovascular disease, and metabolic syndrome due to both antioxidant depletions as well as increased ROS production. [Amini Mohammad Reza (2025); evidence level 1]
• This reduction in oxidized LDL-C leads to reduced release of High-Mobility Group Box 1 (HMGB1), a protein that causes inflammatory effects and tissue damage. [Amini Mohammad Reza (2025); evidence level 1]
• Hypertension is the most significant controllable risk factor for cardiovascular diseases, accounting for about 57% of all cardiovascular-related deaths. [Revueltas Aguero Moura (2025); evidence level 2]
• In addition, hypertension has been strongly associated with an increased risk of coronary heart disease, stroke, chronic kidney disease, and all-cause mortality. [Revueltas Aguero Moura (2025); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For policosanol cholesterol meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Amini Mohammad Reza (2025). The effects of policosanol supplementation on creatinine: a systematic review and dose–response meta-analysis of randomized controlled trials. DOI: 10.1186/s12906-025-04911-0. PMCID: PMC12085850. PMID: 40382621. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12085850/
• Revueltas Aguero Moura (2025). Policosanol (sugarcane wax alcohols) 20 mg/day in Cuban Patients With Grade I Hypertension: A Randomized, Double‐Blind, Multicenter Study. DOI: 10.1111/jch.70126. PMCID: PMC12487964. PMID: 41032504. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12487964/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.